✦ LIBER ✦

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response

✍ Scribed by Y. ROTMAN; B. B. BORG; A. SOZA; J. J. FELD; A. A. MODI; R. LOOMBA; G. LUTCHMAN; E. RIVERA; E. DOO; M. G. GHANY; T. HELLER; A. U. NEUMANN; T. J. LIANG; J. H. HOOFNAGLE

Book ID: 108605887
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 187 KB
Volume: 31
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2010.04263.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low weight predicts neutropenia and pegi

Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C

✍ Y. Rotman; L. Katz; M. Cohen; O. Cohen-Ezra; V. Manhaim; M. Braun; Z. Ben-Ari; R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Peginterferon alfa-2a and ribavirin for

Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

✍ C. D. Howell; L. S. Jeffers; W. Cassidy; K. R. Reddy; S. Hu; J. S. Lee 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Efficacy and tolerability of peginterfer

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study

✍ T. Witthoeft; D. Hueppe; C. John; J. Goelz; R. Heyne; B. Moeller; G. Teuber; S. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB

Randomised clinical trial: the efficacy

Randomised clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3

✍ S. S. Lee; M. Sherman; A. Ramji; S. Greenbloom; M. Elkashab; H. Pluta; N. Hilzen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB

Lower-than-standard dose peg-IFN alfa-2a

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin

✍ O. Weiland; A. Hollander; L. Mattsson; H. Glaumann; K. Lindahl; R. Schvarcz; G. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Black patients with chronic hepatitis C

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin

✍ N. Bräu; E. J. Bini; S. Currie; H. Shen; W. N. Schmidt; P. D. King; S. B. Ho; R. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB